Longeveron Inc., a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024.   In this role, Blass will lead the Company’s technological and manufacturing strategies.   “We are delighted to have Devin join Longeveron at this transformational t...